- Home
- GOSS vs MACI Comparison
GOSS vs MACI Comparison
Compare GOSS & MACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- MACI
- Stock Information
- Founded
- GOSS 2015
- MACI 2024
- Country
- GOSS United States
- MACI United States
- Employees
- GOSS N/A
- MACI N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- MACI
- Sector
- GOSS Health Care
- MACI
- Exchange
- GOSS Nasdaq
- MACI NYSE
- Market Cap
- GOSS 203.3M
- MACI 221.6M
- IPO Year
- GOSS 2019
- MACI 2024
- Fundamental
- Price
- GOSS $1.12
- MACI $10.32
- Analyst Decision
- GOSS Strong Buy
- MACI
- Analyst Count
- GOSS 4
- MACI 0
- Target Price
- GOSS $7.50
- MACI N/A
- AVG Volume (30 Days)
- GOSS 1.6M
- MACI 9.3K
- Earning Date
- GOSS 05-13-2025
- MACI 01-01-0001
- Dividend Yield
- GOSS N/A
- MACI N/A
- EPS Growth
- GOSS N/A
- MACI N/A
- EPS
- GOSS N/A
- MACI N/A
- Revenue
- GOSS $114,701,000.00
- MACI N/A
- Revenue This Year
- GOSS N/A
- MACI N/A
- Revenue Next Year
- GOSS $172.31
- MACI N/A
- P/E Ratio
- GOSS N/A
- MACI $44.17
- Revenue Growth
- GOSS N/A
- MACI N/A
- 52 Week Low
- GOSS $0.50
- MACI $9.95
- 52 Week High
- GOSS $1.55
- MACI $10.35
- Technical
- Relative Strength Index (RSI)
- GOSS 56.55
- MACI N/A
- Support Level
- GOSS $1.06
- MACI N/A
- Resistance Level
- GOSS $1.26
- MACI N/A
- Average True Range (ATR)
- GOSS 0.11
- MACI 0.00
- MACD
- GOSS 0.04
- MACI 0.00
- Stochastic Oscillator
- GOSS 70.09
- MACI 0.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About MACI MELAR ACQUISITION CORP. I
Melar Acquisition Corp I is a blank check company.